We use cookies to help provide you with the best possible online experience. Learn more

Financial Reports

    Interim report January 1- June 30, 2018

    RaySearch Laboratories AB (publ)

    “In the second quarter of 2018, order intake excluding service agreements rose 47 percent to SEK 160 M, which is the highest order intake ever for the second quarter. Net sales declined marginally to SEK 141 M (142) and the operating margin remained unchanged at 19 percent (19), mainly due to the change in accounting policies, but also to positive currency effects. Without application of the new accounting policies, net sales would have risen 15 percent to SEK 162 M and the operating margin would have been 28 percent. Our order backlog including service agreements was SEK 720 M (591) at the end of the period. We feel secure with our long-term strategy and our expansion will continue”, says Johan Löf, CEO of RaySearch.

    SECOND QUARTER (APRIL-JUNE 2018) 

    • Net sales SEK 141.0 M (141.6), of which revenues from RayStation®/RayCare® SEK 126.6 M (127.6) 
    • Profit after tax SEK 20.6 M (20.1), and earnings per share before/after dilution SEK 0.60 (0.59) 
    • Operating profit SEK 26.3 M (26.8) 
    • Cash flow SEK -50.3 M (-13.7) 
    • Order intake excl. service agreements SEK 160.3 M (108.8), of which RayStation/RayCare SEK 151.1 M (98.0)

    HALF-YEAR (JANUARY-JUNE 2018) 

    • Net sales SEK 257.3 M (268.4), of which RayStation/RayCare SEK 233.4 M (240.0) 
    • Profit after tax SEK 32.4 M (46.4), and earnings per share before/after dilution SEK 0.94 (1.35) 
    • Operating profit SEK 40.4 M (60.3) 
    • Cash flow SEK -37.9 M (-16.7) 
    • Order intake excl. service agreements SEK 266.7 M (213.7), of which RayStation/RayCare SEK 248.2 M (191.8) 
    • Order backlog incl. service agreements SEK 719.7 M (591.0) at the end of the period 
    • Order backlog for RayStation/RayCare excl. service agreements SEK 106,0 M (36.0) at the end of the period

     CHANGES TO ACCOUNTING POLICIES

    • IFRS 15 Revenue from Contracts with Customers came into effect on January 1, 2018, which reduced the company’s license revenue from RayStation and RayCare by 19 percent in the second quarter of 2018 and 16 percent in the first half of 2018 compared with the previously applied accounting policy (IAS 18), see Notes 1-2. The changed accounting policies also had a negative impact on net sales and earnings for the past 12-month period. 

    SIGNIFICANT EVENTS DURING THE SECOND QUARTER 

    • RayStation was selected by several leading cancer centers, including the Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) in Germany, Centre intégré universitaire de santé et de service sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (SHUS) in Quebec, Canada, and Advanced Oncotherapy (AVO) in the UK. 
    • Two RayCare orders were received – one from a center in Belgium, and one from a center in Colombia. 
    • Long-term collaborative agreements for RayCare were concluded with Heidelberg University Hospital in Germany and for brachytherapy with Eckert & Ziegler BEBIG. 
    • A research collaboration and long-term licensing agreement for carbon-ion therapy were concluded with NIRS/QST in Japan and will lead to the integration of NIRS’s Microdosimetric Kinetic Model (MKM) in RayStation. 
    • RayStation 8A* was released, with support for the TomoDirectTM treatment mode.

     SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

    • RayCare 2A* was released with a range of new features, including activity and rule-based scheduling for all clinical resources, clinical document management and additional treatment planning functionality. 
    • A long-term collaborative agreement for RayCare was concluded with the Princess Margaret Cancer Center in Toronto, Canada.

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 23, 2018 at 7:45 a.m. CET.  

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO          Tel: +46 8 510 530 00                   E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO                          Tel: +46 70 661 05 59                   E-mail:
    peter.thysell@raysearchlabs.com

     
    ABOUT RAYSEARCH

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to cancer centers all over the world and distributes the products through licensing agreements with leading medical technology companies. RaySearch’s software is currently used by over 2,600 centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com. 

    PDF

    Interim Report January 1 – March 31, 2018

    RaySearch Laboratories AB (publ)

    “During the first quarter 2018, net sales decreased 8 percent to SEK 116 M (127) and operating margin declined to 12 percent (26), primarily due to changes in accounting policies. With unchanged accounting policies, net sales would have been the same as the corresponding quarter of 2017, i.e., SEK 127 M, and the operating margin 19 percent. Cash flow before financing activities improved to SEK 13 M (8). We are secure in our long-term strategy and our expansion is continuing,” says Johan Löf, CEO of RaySearch.
       
     

    THREE MONTHS (JANUARY-MARCH 2018)

    • Net sales SEK 116.3 M (126.8), of which revenues from RayStation/RayCare SEK 104.2 M (112.3)
    • Profit after tax SEK 11.8 M (26.3), and earnings per share before/after dilution SEK 0.34 (0.77) 
    • Operating profit SEK 14.1 M (33.5) 
    • Cash flow for the period SEK 12.3 M (neg: 3.0) 
    • Order intake excl. service agreements SEK 106.6 M (104.9), of which RayStation/RayCare SEK 97.4 M (93.8) 
    • At the end of the period, the order backlog excl. service agreements for RayStation/RayCare was SEK 58.5 M (58.1)
        

    CHANGES TO ACCOUNTING POLICIES 

    • IFRS 15 Revenue from Contracts with Customers applies as of January 1, 2018, which has reduced the company’s license revenue from RayStation by 12.5 percent during the first quarter 2018 compared with previous accounting policy (IAS 18), see Notes 1-2. The changed accounting policies also have a negative impact on net sales and earnings in the last 12-months period.
         

    SIGNIFICANT EVENTS DURING THE FIRST QUARTER 

    • RayStation was selected by several leading cancer centers, including Georgia Proton Treatment Center and Mission Hospital – SECU Cancer Center in the US, CHU de Québec-Université Laval in Canada, and Universitätsmedizin Rostock and Klinikum rechts der Isar der TU München in Germany. 
    • RaySearch entered into a strategic partnership with MD Anderson with intention of improving radiation therapy.
    • In March 2018, 200,000 Class A shares were converted to Class B at the request of a shareholder.
         

    SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

    • RayStation has been selected as the treatment planning system for the two proton and carbon ion therapy centers, Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT), in Germany. 
    • RaySearch has entered into a long-term collaborative agreement for RayCare with Heidelberg University Hospital in Germany.
         

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 9, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00    E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59    E-mail:
    peter.thysell@raysearchlabs.com
        
     

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com. 

    PDF

    RaySearch publishes Annual Report 2017

    For more information, please contact:
    Johan Löf, CEO                       Tel: +46 8 510 530 00          Email: johan.lof@raysearchlabs.com
    Peter Thysell, CFO               Tel: +46 70 661 0559           Email: peter.thysell@raysearchlabs.com

    PDF

    Year-end Report January 1 - December 31, 2017

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch.

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals. 
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US.
          

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com.

    * Regulatory approval is required in some markets.

    PDF